Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AdvaMed 2002 Annual Meeting In Brief

This article was originally published in The Gray Sheet

Executive Summary

Meet Mark Kramer: Former CDRH staff college director becomes FDA's point-of-contact for combination products Feb. 25. Working within the FDA ombudsman's office, Kramer will canvass opinions from internal and external stakeholders, advocate more complex reviews of combination products, and navigate firms' requests for designation. At the AdvaMed 2002 Annual Meeting in Carlsbad, California, Center for Biologics Evaluation & Research Deputy Director Jesse Goodman outlined Kramer's role - to "deal with specific problems, interact with manufacturers, and sort of do a better job of bringing all of us to the table to update intercenter agreements." In addition, Kramer will help develop standard operating procedures for intercenter collaboration and consultation. As the first in a series of public meetings devoted to jurisdictional issues, FDA anticipates hosting a May public meeting on tissue-engineered devices. Kramer's background includes experience working in the device industry and CDRH's Office of Device Evaluation...

You may also be interested in...



Federal Diagnostic Research Funds Will Head Off Future Epidemics – CBER

CBER plans to create financial incentives for companies to develop diagnostic technologies for pathogens before the diseases become prevalent, according to center director Jesse Goodman

Federal Diagnostic Research Funds Will Head Off Future Epidemics – CBER

CBER plans to create financial incentives for companies to develop diagnostic technologies for pathogens before the diseases become prevalent, according to center director Jesse Goodman

Kramer Continues Combo Product Stewardship, Fosters Intercenter Consults

FDA Office of Combination Products Director Mark Kramer will be assisted by Suzanne O'Shea, who is leaving the Office of the Ombudsman to serve as product assignment officer

Related Content

UsernamePublicRestriction

Register

MT016203

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel